Norcia Anthony M

Discovery and clinical translation of novel glaucoma biomarkers.

Here we review recent progress in the development of novel biomarkers for glaucoma in the context of disease pathophysiology and we propose future steps for the field, including integration of exploratory biomarker outcomes into prospective therapeutic trials.

Preferential Loss of Contrast Decrement Responses in Human Glaucoma.

The observed pattern of preferential loss of decremental responses in human glaucoma is consistent with prior reports of selective damage to OFF retinal ganglion cells in murine models and in data from human ERG and retinal imaging.

Glaucoma Classification Through SSVEP-Derived ON- and OFF-Pathway Features.

Our findings highlight the informational value of signal phase, a metric often omitted in applications of the SSVEP to glaucoma and other optic neuropathies.